Last reviewed · How we verify
Cell-derived influenza vaccine
Novartis Vaccines' cell-derived influenza vaccine is currently on the market, positioning the company as a player in the seasonal flu vaccine segment. A key strength of this vaccine is its use of cell culture technology, which can offer advantages in production flexibility and speed compared to traditional egg-based methods. The primary risk to consider is the expiration of the key composition patent in 2028, which could lead to increased competition from generic manufacturers.
At a glance
| Generic name | Cell-derived influenza vaccine |
|---|---|
| Sponsor | Novartis Vaccines |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- pH1N1 Blinded Challenge Study (PHASE1)
- A/Texas Flu Challenge (PHASE1)
- Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older (PHASE3)
- Spirulina Oral Supplement for Enhancing Host Resilience to Virus Infection (PHASE3)
- Immunogenicity Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection (PHASE3)
- Inactivated Split Virus Seasonal Influenza Vaccine (Vero Cell-Derived) (PHASE3)
- Study on Safety and Efficacy of Two Doses of PRS CK STORM in the Modulation of the Cytokine Storm for the Treatment of Acute Respiratory Distress Syndrome (ARDS) Caused by SARS-Cov-2, Influenza A, Influenza B and Respiratory Syncytial Virus (RSV) (PHASE1, PHASE2)
- The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cell-derived influenza vaccine CI brief — competitive landscape report
- Cell-derived influenza vaccine updates RSS · CI watch RSS
- Novartis Vaccines portfolio CI